Advertisement
Screener

OCULAR THERAPEUTIX, INC (OCUL) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

OCULAR THERAPEUTIX, INC Increase (Decrease) in Deferred Revenue

OCULAR THERAPEUTIX, INC (OCUL) reported Increase (Decrease) in Deferred Revenue of -$42.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-08.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-08

  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for the quarter ending 2016-12-31 was $0.00.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was $0.00.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for the quarter ending 2016-06-30 was $0.00.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for the quarter ending 2016-03-31 was -$42.00K, a 167.74% decline year-over-year.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for fiscal 2016 was -$42.00K.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for fiscal 2015 was -$146.00K.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for fiscal 2014 was -$62.00K, a 124.80% decline from fiscal 2013.
  • OCULAR THERAPEUTIX, INC increase (decrease) in deferred revenue for fiscal 2013 was $250.00K.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$0.00
derived: sum of 2 quarters · filed 2018-03-08
$0.00
derived: sum of 3 quarters · filed 2018-03-08
-$42.00K
10-K · filed 2018-03-08
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$0.00
derived: sum of 2 quarters · filed 2017-11-07
-$42.00K
10-Q · filed 2017-11-07
-$83.00K
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
-$42.00K
10-Q · filed 2017-08-08
-$83.00K
derived: sum of 3 quarters · filed 2018-03-08
-$125.00K
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31-$42.00K
10-Q · filed 2017-05-05
-$83.00K
derived: sum of 2 quarters · filed 2018-03-08
-$125.00K
derived: sum of 3 quarters · filed 2018-03-08
-$250.00K
derived: sum of 4 quarters · filed 2018-03-08
2015-12-31-$41.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
-$83.00K
derived: sum of 2 quarters · filed 2018-03-08
-$208.00K
derived: sum of 3 quarters · filed 2018-03-08
-$146.00K
10-K · filed 2018-03-08
2015-09-30-$42.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
-$167.00K
derived: sum of 2 quarters · filed 2016-11-09
-$105.00K
10-Q · filed 2016-11-09
2015-06-30-$125.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
-$63.00K
10-Q · filed 2016-08-09
2015-03-31$62.00K
10-Q · filed 2016-05-10
2014-12-31-$62.00K
10-K · filed 2017-03-10
2013-12-31$250.00K
10-K · filed 2016-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Zai Lab Ltd (ZLAB)$2.241B-113.34
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05